Press Release

MONTREAL, May 10th, 2023 – Replicor Inc. had its latest clinical data on NAPs in HBV and HDV infection highlighted at the 2023 Digestive Disease Weekly Meeting held May 6-9th in Chicago, IL, USA (see here).

Dr. Christiane Stern (Hôpital Beaujon, Clichy, France) presented Replicor’s latest clinical data on the safety and tolerability of TDF + REP 2139-Mg in decompensated cirrhosis in an oral presentation on advances in HBV / HDV therapeutics.

Replicor’s latest data on the expanding French cohort of bulevirtide failure patients with compensated cirrhosis receiving TDF + REP 2139-Mg + 90µg pegIFN was awarded a poster of distinction and was presented by Dr. Andrew Vaillant, CSO, Replicor Inc. and Dr. Stern.

Both of these presentations highlighted groundbreaking data showing that REP 2139-Mg is safe, well tolerated and able to achieve very rapid reversal of ascites and re-compensation of cirrhosis in patients with decompensated cirrhosis and reversal of esophageal varices when present. Strong antiviral activity against HBV and HDV and normalization of liver function accompanies these rapid clinical benefits and has already led to durable control of HBV and HDV infection after removal of NAP therapy in two patients.

Dr. Vaillant commented, “We are very pleased at the recognition of our latest clinical data with NAPs at DDW 2023. Our ongoing compassionate access program (see here) continues to show how NAP therapy can have transformative effects in patients with the most advanced liver disease with chronic HBV and HDV infection. We look forward to showcasing upcoming developments at future meetings.”

These presentations can be accessed at http://replicor.com/conference-presentations/.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.